Articles tagged with Multiple Sclerosis
Researchers at Oregon Health & Science University have developed a compound that successfully promotes rebuilding of damaged nerve cell protective sheath, reversing MS symptoms. The discovery may lead to clinical trials in humans with MS or other neurodegenerative conditions.
A recent study by Kessler Foundation researchers linked deficits in social cognition with symptoms of fatigue, depressive symptomatology, and anxiety in individuals with multiple sclerosis. The study highlights the interplay between social cognition, mood, and fatigue in MS patients.
The American Academy of Neurology has issued a new guideline recommending that people with multiple sclerosis receive recommended vaccinations, including yearly flu shots. The guideline updates previous recommendations and emphasizes the importance of preventing infections through vaccine use in MS patients.
A recent study found that Medicare patients with multiple sclerosis have seen a significant increase in out-of-pocket costs for their medications over the past decade. The cost of these drugs has risen more than sevenfold, affecting not only the patients but also the healthcare system as a whole.
Researchers identify various disease mechanisms underlying progressive MS, highlighting the need for precise therapy approaches targeting different pathomechanisms. Financial obstacles, including patent expirations, also hinder the development of new drugs.
A University at Buffalo-led study found that a vegetable-rich diet can improve fatigue in multiple sclerosis patients by increasing good cholesterol levels. The results suggest that lipid metabolism plays a crucial role in fatigue and may provide new treatment options for this debilitating symptom.
A recent NIH study found that chronic active lesions in the brain, marked by dark rimmed spots, are a hallmark of more aggressive and disabling forms of multiple sclerosis. The study suggests that these lesions may play a role in progressive MS and offers hope for developing new treatments.
A new Stanford study found that stimulating a protective immune cell class, CD8 T cells, may reduce autoimmune disease severity. In a mouse model of multiple sclerosis, injecting mice with peptides recognized by these cells reduced disease severity and killed disease-causing immune cells.
A large-scale analysis of over 200,000 individuals found no positive correlation between vaccinations and the development of multiple sclerosis. MS patients were statistically less likely to receive vaccinations before diagnosis than comparator groups.
A $1,825,742 NIH grant will fund a randomized controlled trial of strategy-based cognitive training in individuals with multiple sclerosis. The study aims to develop a treatment that improves everyday functioning and neuropsychological performance in those affected by the condition.
Researchers at the Center for BrainHealth have developed a novel diagnostic method for multiple sclerosis that uses 3D images of brain lesions to determine healing capacity. The technology has the potential to help doctors tailor treatment plans and improve patient outcomes.
PCORI is funding two projects to expand use of PCORI-funded research findings in real-world practice. A $1.4 million project aims to increase lung cancer screening rates, while an $860,000 project seeks to improve care for adolescents with TBI through a self-guided online therapy program.
Researchers have discovered that projection neurons are damaged by immune cells in MS patients' brains, leading to brain shrinkage and cognitive changes. This finding provides a platform for targeted therapies to be developed.
Researchers have identified ceramides, a type of lipid, as key contributors to neuronal damage in progressive multiple sclerosis (MS) patients. The study found that exposure to cerebrospinal fluid from progressive MS patients caused mitochondrial dysfunction and increased energy demand, leading to neuronal demise.
A single-center study of 453 children with multiple sclerosis found a significant association between obesity and increased risk of pediatric MS. The study also explored the response of first-line therapy in obese children with MS, but no conclusive findings were reported.
Researchers suggest that viruses hiding in our DNA could be causing some of our deadliest neurological diseases. Studies link HERV reactivation to autoimmune attacks in multiple sclerosis and peripheral demyelinating disease CIDP.
A new study has shown that people with progressive multiple sclerosis (MS) experience significant improvements in movement and balance thanks to a specialized standing frame. The intervention also appeared cost-effective, leading researchers to conclude it could be routinely implemented within MS care throughout the UK.
A comprehensive study of MS patients found that gadolinium deposition occurs early in the disease, but does not have a clinical impact. However, male patients showed more deposition than female patients, which may be related to dosage based on weight.
A novel PET tracer has been used to detect abnormal inflammation in the grey matter of patients with progressive multiple sclerosis, linked to physical disability and brain atrophy. The study provides a new tool for assessing disease progression and predicting treatment effects.
A 65-year follow-up study of nearly 7,000 Norwegian patients with multiple sclerosis found an overall risk of developing cancer 14% higher than the general population. Respiratory cancer risk was particularly high at 66%, while urinary and central nervous system cancer risks were also significantly increased.
A new study published in PNAS reveals that the HERV-W envelope protein drives CNS microglial cells to damage myelinated axons in MS patients. Clinical trials have shown promising results with temelimab, an ENV-neutralising antibody that blocks the retrovirus's activity.
A recent study by Kessler Foundation researchers found evidence for differential effects of progressive MS on cognitive and affective Theory of Mind. The study used Virtual Assessment of Mentalising Ability (VAMA) to measure Theory of Mind in individuals with progressive MS, who showed poorer performance on the cognitive ToM subtest co...
Researchers Drs. Shenoy Handiru and Katie Lancaster at Kessler Foundation will investigate novel ways to improve rehabilitative care for disabilities caused by stroke and multiple sclerosis. The projects aim to enhance hand function in stroke patients and alleviate feelings of stress and anxiety in individuals with MS.
A study of 5,704 patients with MS found that those with pediatric-onset disease had lower test scores and faster declining cognitive abilities. Patients with pediatric-onset MS were also more likely to experience cognitive impairment compared to those with adult-onset MS.
Researchers discovered 12 genes that increase MS risk in families with multiple members affected by the disease. They found a common biological process leading to increased inflammation, paving the way for personalized treatments and preventative strategies.
A new nanotechnology treatment using exosomes extracted from bone marrow stem cells has reversed MS symptoms in mice by rejuvenating lost motor skills and decreasing nerve damage. The treatment will be tested on humans in early 2020, initially on people with Type 1 diabetes.
A recent study by I.R.C.C.S. Neuromed found that obese patients with multiple sclerosis have a greater risk of presenting higher EDSS scores and experiencing increased central inflammation. The research suggests that excessive body weight and altered lipid profiles may be associated with worsened clinical expression of the disease.
In a mouse model of atypical EAE, researchers found that dysregulated neutrophils cause damage and exhibit hyper-activated phenotypes, producing excessive reactive oxygen species. Neutralizing treatments reduced disease severity, highlighting the detrimental role of neutrophils in autoimmune neuroinflammation.
The International Pediatric MS Study Group has released updated standards for clinical trials involving children and teens with multiple sclerosis. The new recommendations prioritize pharmacokinetic/pharmacodynamic studies, phase 3 trials in adults considering teenagers, and open-label extension studies to ensure high-quality evidence ...
Researchers found simvastatin helped delay disability worsening and slow brain atrophy in people with secondary progressive MS. The study suggests statins may have independent effects on the disease, beyond cholesterol lowering.
Researchers discovered that fibrinogen, a blood-clotting protein, plays a role in multiple sclerosis relapses. In a mouse model, injecting EVs containing fibrinogen activated CD8+ immune cells, leading to relapsing-remitting disease.
A large-scale assessment of over 20,000 patients found that reading office visit notes offers considerable benefits, particularly for those from underserved populations. Patients reported increased control and understanding of their care, as well as improved adherence to treatment plans and medications.
The study found that out-of-pocket costs for MS drugs increased 20 times between 2004 and 2016, with people in high-deductible plans paying twice as much. The annual cost of treating neurologic disorders in the US is over $500 billion.
A Tel Aviv University study reveals that gene deletion in neurons is responsible for hypersocial behavior in Williams syndrome, caused by myelin sheath deficits. The research also identifies potential treatments using FDA-approved MS drugs.
A scientific breakthrough provides new hope for people with multiple sclerosis, as researchers have developed a compound that stimulates repair of the protective sheath that covers nerve cells in the brain and spinal cord. The study, published in JCI Insight, shows promising results in repairing damaged myelin without severe side effects.
A study by UMass Amherst researchers explores the effects of tai chi and mindfulness meditation on people with multiple sclerosis (MS), comparing their impact on physical balance and psychosocial well-being. The pilot study aims to validate community-based classes and lead to a larger scale study.
A longitudinal study found a correlation between ceramide levels, body mass index, and disease progression in MS patients. Individuals with higher ceramide levels experienced greater loss of motor skills and more brain injury over two years.
A study using 7-Tesla MRI detected cortical lesions in 80% of MS patients, which were strongly correlated with neurological disability and disease progression. Cortical lesions accumulated in grooves on the brain's surface called sulci, suggesting a new approach to evaluating MS progression.
A recent study found that nearly 18% of multiple sclerosis patients were misdiagnosed before receiving treatment at two major Los Angeles medical centers. The study revealed that many patients spent an average of four years being treated for MS before receiving a correct diagnosis.
A Phase 1b clinical trial successfully induces immune tolerance to autoimmune targets in patients with multiple sclerosis and neuromyelitis optica. The treatment involves introducing peptide-loaded tolerogenic dendritic cells, which stimulate the production of IL-10 and promote immune tolerance.
A new study published in Neurology found no link between dietary intake of minerals like zinc, iron, and other minerals with the development of multiple sclerosis. The study involved over 80,000 female nurses and found no association between mineral intake and MS risk.
Researchers optimized a 20-nucleotide DNA aptamer to improve its binding properties to myelin, a promising lead molecule for multiple sclerosis therapy. The study provides the first evidence of cross-reactivity with human brain cells.
Researchers found that brain stem cells from primary progressive MS patients act and look older than normal cells, affecting myelin production. Blocking a specific protein may improve oligodendrocyte growth and offer new treatment options.
A new study attributes the link between earlier puberty and multiple sclerosis (MS) to body mass index (BMI), finding that increased BMI is also linked to a greater risk of MS. Researchers analyzed genetic data from over 329,000 women and found that people with an earlier age of puberty were more likely to develop MS.
A UBC study found that beta interferon treatment for multiple sclerosis patients is associated with a 32% lower mortality risk compared to those who did not take the drug. The study followed nearly 6,000 people with MS in Canada and France over two decades.
Virginia Tech professor Webster Santos has received a grant to discover drugs that inhibit a small molecule transporter, which modulates the immune system and could treat multiple sclerosis. The collaboration aims to develop SPNS2 inhibitors for treating MS and metastatic cancers.
A new study found that non-contrast MRI is just as effective as contrast-enhanced MRI for monitoring disease progression in MS patients. The study used image subtraction techniques to detect newly occurring lesions with high sensitivity.
A new study found that the risk of relapse in multiple sclerosis (MS) is lower during and after pregnancy than previously thought. Women with MS can have children without an increased risk of relapses, according to a preliminary study published by the American Academy of Neurology.
Researchers examine experiences of families with pediatric onset MS, finding complex diagnostic odyssey and high emotional toll. Disease-modifying treatments improve outcomes, but long-term emotional support needed for patients' families.
A study of 135 people with multiple sclerosis found that drinking around 290 calories per day of soda or other sugar-sweetened beverages linked to more severe symptoms and a higher level of disability. Those who seldom consumed these beverages had less severe symptoms, highlighting the potential negative impact on MS progression.
Researchers found that high flavonoid cocoa powder improved fatigue in people with multiple sclerosis by reducing mental and physical fatigue. Participants who drank the high flavonoid version showed a moderate effect on fatigability and improvements in pain symptoms, while those drinking low flavonoid cocoa saw no significant benefits.
Researchers at the Advanced Science Research Center have identified a mechanism by which metabolites inhibit epigenetic changes in brain-homing immune cells, which play a key role in multiple sclerosis. The discovery could lead to more specific and effective MS therapies.
Researchers will examine how individuals with MS process outcomes of their actions during cooperative interactions, aiming to maximize their competence in social interactions. The study will focus on the impact of delayed reciprocation vs immediate reciprocation on outcome processing in individuals with MS.
A new study from the University of British Columbia found that neighbourhood income and education level are associated with an increased risk of disability progression in patients with multiple sclerosis. The research suggests that modifiable lifestyle factors, such as diet and exercise, could be involved in this relationship.
Dr. Ekaterina Dobryakova, a researcher at Kessler Foundation, has been honored with the International Neuropsychological Society's Early Career Award for her work on traumatic brain injury and multiple sclerosis. Her research focuses on noninvasive interventions to address cognitive deficits caused by these conditions.
Researchers have developed a new compound that shows promise in treating multiple sclerosis by reducing inflammation and promoting neuroprotection and remyelination. The compound, based on chloroindazole, has been found to be effective in improving primary symptoms in a mouse model of the disease.
A new study found that multiple sclerosis patients with food allergies experienced a higher rate of disease activity and increased likelihood of new lesions compared to those without food allergies. The association highlights the potential role of the gut in MS immune dysregulation.
Researchers created a high-resolution map of the brain's immune system, showing that all microglia have the same core signature but adapt differently depending on their function. This discovery is significant for understanding brain diseases like multiple sclerosis and Alzheimer's.
A team of scientists discovered that Blimp1 prevents the loss of identity in regulatory T cells, a type of immune cell that controls inflammation. This finding has implications for therapies against inflammatory autoimmune diseases such as multiple sclerosis and arthritis.
A recent study published in Nature Communications identifies Satb1 as a protein regulator that induces the pathogenic properties of Th17 cells, leading to multiple sclerosis and other inflammatory autoimmune disorders. By targeting Satb1 gene expression in Th17 cells, novel treatments may be developed to alleviate or eliminate disease ...